Phase 3 Recruiting NIH
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in Minnesota: - Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
- Essentia Health Cancer Center — Duluth, Minnesota
- Miller-Dwan Hospital — Duluth, Minnesota
- Essentia Health Hibbing Clinic — Hibbing, Minnesota
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in Minnesota: - Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Minnesota Oncology - Burnsville — Burnsville, Minnesota
- Mercy Hospital — Coon Rapids, Minnesota
- Fairview Southdale Hospital — Edina, Minnesota
- Saint John's Hospital - Healtheast — Maplewood, Minnesota
Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Minnesota: - Research Site — Burnsville, Minnesota
- Research Site — Duluth, Minnesota
- Research Site — Rochester, Minnesota
Phase 2, Phase 3 Recruiting Industry
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizum…
Sponsor: Bicara Therapeutics
NCT ID: NCT06788990
Sites in Minnesota: - Site #0156 — Maplewood, Minnesota
- Site #0146 — Rochester, Minnesota
Phase 3 Recruiting Industry
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Sponsor: Merus B.V.
NCT ID: NCT06525220
Sites in Minnesota: - Site 155 — Minneapolis, Minnesota
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Sites in Minnesota: - Minnesota Oncology Hematology, PA ( Site 8003) — Edina, Minnesota
Phase 2 Recruiting Network
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Minnesota: - Riverwood Healthcare Center — Aitkin, Minnesota
- Mayo Clinic Health System in Albert Lea — Albert Lea, Minnesota
- Essentia Health - Baxter Clinic — Baxter, Minnesota
- Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Minnesota: - Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Minnesota Oncology - Burnsville — Burnsville, Minnesota
- Mercy Hospital — Coon Rapids, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
Phase 2 Recruiting NIH
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in Minnesota: - Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Minnesota: - Local Institution - 2132 — Saint Paul, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…
Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Minnesota: - HealthPartners Cancer Research Center — Saint Louis Park, Minnesota
- HealthPartners Cancer Research Center (Regions Hospital) — Saint Paul, Minnesota
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Minnesota: - Masonic Cancer Center University of Minnesota — Minneapolis, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…
Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Minnesota: - Mayo Rochester — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Minnesota: - Mayo Clinic in Rochester, Minnesota — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered eithe…
Sponsor: Aulos Bioscience, Inc.
NCT ID: NCT05267626
Sites in Minnesota: - Minnesota Oncology and Hematology PA — Minneapolis, Minnesota
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Minnesota: - Exelixis Clinical Site #68 — Rochester, Minnesota
Phase 1 Recruiting Industry
This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab…
Sponsor: Fate Therapeutics
NCT ID: NCT07216105
Sites in Minnesota: - University of Minnesota Masonic Cancer Center — Minneapolis, Minnesota
Phase 1 Recruiting Academic/Other
Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion stu…
Sponsor: SparX Biotech(Jiangsu) Co., Ltd.
NCT ID: NCT06259552
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 4 Recruiting Industry
TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them fro…
Sponsor: Pfizer
NCT ID: NCT06952660
Sites in Minnesota: - M Health Fairview Clinics and Specialty Center — Burnsville, Minnesota
- M Health Fairview Clinics and Surgery Center — Edina, Minnesota
- M Health Fairview Clinics and Surgery Center — Maple Grove, Minnesota
- M Health Fairview St. John's Hospital — Maplewood, Minnesota
- M Health Fairview Clinics and Surgery Center — Minneapolis, Minnesota
Recruiting Industry
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
Sponsor: Tempus AI
NCT ID: NCT06163534
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Recruiting Academic/Other
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus…
Sponsor: Mayo Clinic
NCT ID: NCT05051722
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
NA Recruiting NIH
This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a comm…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07281430
Sites in Minnesota: - Minneapolis VA Medical Center — Minneapolis, Minnesota
NA Recruiting Academic/Other
This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection, in a screening population, with and without chronic gastroesophageal reflux d…
Sponsor: Mayo Clinic
NCT ID: NCT03961945
Sites in Minnesota: - Mayo Clinic Health Systems - Austin — Austin, Minnesota
- Mayo Clinic Health Systems - Mankato — Mankato, Minnesota
- Mayo Clinic Rochester — Rochester, Minnesota
Recruiting Academic/Other
The primary goal of this study is to examine whether recurrence of HPV-associated OPSCC can be predicted by two factors: 1) mutations in genes called TRAF3 and CYLD, and 2) measurements of circulating HPV DNA in blood plasma. The study wil…
Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT04564989
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota